Axsome Therapeutics’ (AXSM) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report released on Wednesday,Benzinga reports. They currently have a $153.00 price target on the stock. Cantor Fitzgerald also issued estimates for Axsome Therapeutics’ FY2025 earnings at ($4.15) EPS.

Other equities research analysts have also recently issued research reports about the company. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a report on Tuesday. Royal Bank of Canada raised their price objective on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a research note on Wednesday. Leerink Partners lifted their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. Robert W. Baird lifted their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $176.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $157.64.

Axsome Therapeutics Trading Up 6.7 %

Shares of Axsome Therapeutics stock opened at $137.75 on Wednesday. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.37. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $139.13. The company has a market capitalization of $6.72 billion, a P/E ratio of -23.00 and a beta of 1.05. The business has a 50 day moving average price of $101.29 and a 200 day moving average price of $94.84.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. Sell-side analysts anticipate that Axsome Therapeutics will post -2.26 EPS for the current fiscal year.

Insider Activity

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 22.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. TFG Asset Management GP Ltd bought a new position in shares of Axsome Therapeutics during the 4th quarter valued at approximately $3,490,000. GF Fund Management CO. LTD. purchased a new stake in Axsome Therapeutics in the fourth quarter worth $86,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new stake in Axsome Therapeutics in the fourth quarter worth $2,853,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Axsome Therapeutics by 20.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company’s stock worth $4,877,000 after buying an additional 9,928 shares in the last quarter. Finally, Woodline Partners LP grew its position in shares of Axsome Therapeutics by 36.8% during the 4th quarter. Woodline Partners LP now owns 408,441 shares of the company’s stock worth $34,558,000 after buying an additional 109,872 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.